NPPA Revises Ceiling Price of 6 Formulations, details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the ceiling price of 6 scheduled formulations, including acetyl salicylic acid, calcium carbonate, dapsone, medroxy progesterone acetate, rifampicin, and others.
The ceiling price of the acetyl salicylic acid has been set at Rs. 0.28 per tablet, and the ceiling price for the calcium carbonate tablet (250 mg) has been set at Rs. 2.47 per tablet .
On the other hand, the ceiling price for the 50 mg Dapsone tablet, the 5 mg Medroxy Progesterone Acetate tablet, and the 450 mg Rifampicin tablet has been set at Rs 0.30, Rs 3.8, and Rs 5.62 per tablet, respectively.
Furthermore, the ceiling price of Rs 11.57 per condom has been fixed.
"Ceiling price" refers to a price fixed by the government for scheduled formulations in accordance with the provisions of the Drugs (Prices Control) Order, 2013. The ceiling price is the maximum price to the retailer (excluding taxes, if any) for the given product.
Scheduled formulation means any formulation included in the First Schedule, whether referred to by generic versions or brand names (mainly products covered under the National List of Essential Medicines are scheduled formulations). In other words, all medicines that are covered in the National List of Essential Medicines, which are notified in Schedule 1 by the government, are scheduled formulations.
This came in exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, has fixed the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
Price Revision as per Annual Wholesale Price Index (WPI) @ 1.74028% increase
Sl. No. | Medicines | Dosage form and Strength | Unit | Ceiling price (wef 1.4.2025 with WPI @ 1.74028 %) (in Rs.) | Existing S.O. No. & Date | |
(1) | (2) | (3) | (4) | (5) | 6(a) | 6(b) |
1. | Acetyl Salicylic Acid | Tablet 300 mg | 1 Tablet | 0.28 | 1549 (E) | 26-03-2024 |
2. | Calcium carbonate | Tablet 250 mg | 1 Tablet | 2.47 | 1549 (E) | 26-03-2024 |
3. | Condoms | 1 Condom | 11.57 | 1549 (E) | 26-03-2024 | |
4. | Dapsone | Tablet 50 mg | 1 Tablet | 0.30 | 1549 (E) | 26-03-2024 |
5. | MedroxyProgesterone Acetate | Tablet 5 mg | 1 Tablet | 3.78 | 1549 (E) | 26-03-2024 |
6. | Rifampicin | Tablet 450 mg | 1 Tablet | 5.62 | 1549 (E) | 26-03-2024 |
Furthermore, the notice added,
(a) The ceiling prices are applicable with effect from 1.4.2025 (ceiling prices are inclusive of the Wholesale Price Index (WPI) @ 1.74028% for the year 2024 over 2023).
(b) All manufacturers of scheduled formulations selling the branded or generic or both versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the government shall revise the prices of all such formulations downward, not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any.
(c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. & date as specified in columns 6(a) & 6(b) in the above table (plus Goods and Services Taxes as applicable, if any) may revise the existing MRP of their formulations on the basis of WPI @ 1.74028% for year 2024 over 2023 in accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the government on the ceiling price mentioned in column (5) of the above-said table.
(e) Information about the revision, if carried out, shall be forwarded to the government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), along with interest thereon from the date of overcharging.
(f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of notification as per paragraph 24 of the DPCO, 2013, to NPPA through IPDMS and submit a copy to the state drug controller and dealers.
(g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013, such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form-I as specified under Schedule-II of the DPCO, 2013.
(i) The manufacturers of the above-said scheduled formulations shall furnish a quarterly return to the NPPA in respect of the production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the DPCO, 2013, read with the Essential Commodities Act, 1955.
(k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification stand(s) superseded.
To view the full notice, click the link below:
